Clinical Trials Arena

159 articles in the TruthFoundry index. Each links out to the original.

• HealthBio launches multi-centre clinical trial for PTLDS treatment Inflamexa · Biotechnology firm HealthBio initiates trial of Inflamexa for post-treatment Lyme disease syndrome.
• Podcast Examines Principal Investigator Oversight In Modern Clinical Trials · Gilead VP Tracy Vanderslice discusses clinical trial PI oversight challenges on podcast.
• Clinical Trials Arena paywall gate requires login for premium content · Clinical Trials Arena displays an access gate requiring authentication for premium content.
• Sanofi and Teva's Duvakitug Shows High Remission Rates in IBD Phase IIb Trial · Sanofi and Teva's IBD drug duvakitug achieved high clinical remission in a Phase IIb trial for ulcerative colitis and Crohn's disease.
• Amgen and AstraZeneca Report Positive Phase III Results for Tezspire in EoE · Amgen and AstraZeneca report Tezspire met co-primary endpoints in Phase III trial for eosinophilic oesophagitis.
• Shionogi and F2G Present New Data on Olorofim for Invasive Aspergillosis · Shionogi and F2G report Phase III data showing olorofim offers long-term non-inferiority and faster hospital discharge for invasive aspergillosis.
• AstraZeneca and Oracle Partner to Test AI in Clinical Trial Recruitment · AstraZeneca and Oracle signed a non-binding agreement to test AI for clinical trial recruitment and patient care.
• Hutchmed and AstraZeneca share positive NSCLC outlook at ESMO26 · Hutchmed and AstraZeneca express a positive outlook on non-small cell lung cancer at ESMO26.
• Rapport Therapeutics RAP-219 succeeds in Phase II bipolar mania trial · Rapport Therapeutics announced positive Phase II results for bipolar mania drug RAP-219.
• EyePoint cuts jobs, ends Phase III trial after duravyu miss · EyePoint Pharmaceuticals ends Phase III trial and cuts 53% of workforce after duravyu failed its primary endpoint in wAMD.
• Veradermics stock rises 6% after successful male hair loss drug trial · Veradermics shares gained 5.9% following positive Phase III results for oral hair loss drug VDPHL01.
• BRIA-ABC bets on survival in metastatic breast cancer · BRIA-ABC invests in survival strategies for metastatic breast cancer patients.
• FDA's Real-Time Clinical Trials Initiative Forces Procurement Strategy Overhaul · FDA's Real-Time Clinical Trials initiative requires supply chains to shift from batch processing to real-time data integration.
• Lilly's Omvoh Achieves 50% Remission in Paediatric Ulcerative Colitis Trial · Eli Lilly's Omvoh achieved a 50% clinical remission rate in paediatric ulcerative colitis patients in the SHINE-2 study.
• Zentalis reports interim survival data for azenosertib ovarian cancer trial · Zentalis publishes DENALI Part 1b trial interim survival results for azenosertib.
• Cyrano Therapeutics CYR-064 Phase II Trial Meets Safety Endpoint for Smell Loss · Cyrano Therapeutics reports CYR-064 met primary safety endpoint in Phase II trial for post-viral smell loss.
• MacroGenics Doses First Patient in Phase I Trial for MGC030 · MacroGenics dosed the first patient in a Phase I study of its investigational therapy MGC030 for advanced solid tumours.
• Study Links Air Pollution and Temperature to Type 2 Diabetes Risk · Research indicates that exposure to air pollution and high temperatures increases the risk of developing type 2 diabetes.
• Merz Completes Early Phase III Trials for Xeomin Migraine Prevention · Merz Therapeutics finished patient enrollment in global Phase III trials for Xeomin migraine prevention six months ahead of schedule.
• Verastem KRAS inhibitor VS-7375 posts positive trial results across three cancers · Verastem Oncology will advance KRAS inhibitor VS-7375 to Phase III trials after positive clinical data.
• Vanda Pharmaceuticals Halts Social Anxiety Drug Development After Phase III Failure · Vanda Pharmaceuticals pauses late-stage trials for VQW-765 after failing to meet primary endpoints in a social anxiety disorder study.
• Spinogenix adds autism Phase IIb study to CLARITY basket trial · Biopharma firm Spinogenix expands CLARITY trial to test codabakalner for autism.
• Pilatus Biosciences Doses First Patient in PLT012 HCC Trial · Pilatus Biosciences dosed the first patient in Hong Kong for its Phase I trial of PLT012 for hepatocellular carcinoma.
• Arrowhead's ARO-MAPT Reduces Tau in Healthy Volunteers Ahead of Alzheimer's Trials · Arrowhead's RNAi therapy ARO-MAPT reduced CSF tau by up to 85% in a Phase I/IIa trial with healthy volunteers.
• UK MHRA Unveils 2030 Strategy to Accelerate Personalized Healthcare and AI · The UK's MHRA launches a 2030 strategy to speed up drug approvals and integrate AI into regulation.
• Clinical Trials Arena promotes free premium content registration · Clinical Trials Arena advertises free premium industry content for registered users.
• IgniteData and RealTime partner to automate clinical trial data transfers · Clinical software firms IgniteData and RealTime announce integration for automated trial data transfers.
• Calluna Pharma completes dosing for Phase II AURORA IPF drug trial · Calluna Pharma finished patient dosing in its Phase II CAL101 trial for idiopathic pulmonary fibrosis.
• BioNTech mRNA Cancer Vaccine Misses PFS Endpoint in HNSCC Trial · BioNTech's BNT113 vaccine failed to meet progression-free survival goals in a Phase II/III head and neck cancer trial.
• Regeneron Reports Sustained Efficacy for FOP Drug Pasatru at 84 Weeks · Regeneron reports Phase III data showing Pasatru prevented new bone lesions in adults with fibrodysplasia ossificans progressiva.